microRNA detection in feces, sputum, pleural effusion and urine: Novel tools for cancer screening (Review)

Oncology Reports

Volumn 30, Issue 2, 2013, Pages 535-544

  Xiao, Yu Feng ^a   Yong, Xin ^a   Fan, Ya Han ^a   Lü, Mu Han ^a   Yang, Shi Ming ^a   Hu, Chang Jiang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cancer; Feces; microRNAs; Pleural effusion; Sputum; Urine

Indexed keywords

MICRORNA; MICRORNA 100; MICRORNA 126; MICRORNA 134; MICRORNA 143; MICRORNA 145; MICRORNA 151; MICRORNA 155; MICRORNA 182; MICRORNA 183; MICRORNA 192; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 21; MICRORNA 222; MICRORNA 24; MICRORNA 26A; MICRORNA 30D; MICRORNA 345; MICRORNA 375; MICRORNA 452; MICRORNA 486; MICRORNA 93; MICRORNA 96; TUMOR MARKER; UNCLASSIFIED DRUG;

BIOLUMINESCENCE; CANCER PROGNOSIS; CANCER SCREENING; COLON CANCER; DOWN REGULATION; EARLY DIAGNOSIS; FECES; FLUORESCENCE CORRELATION SPECTROSCOPY; HUMAN; IN SITU HYBRIDIZATION; LUNG CANCER; MICROARRAY ANALYSIS; NORTHERN BLOTTING; PLEURA EFFUSION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SPUTUM; UPREGULATION; URINARY TRACT CANCER; URINE;

EARLY DETECTION OF CANCER; FECES; HUMANS; MICRORNAS; NEOPLASMS; PLEURAL EFFUSION; SPUTUM;

EID: 84879680924     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2525     Document Type: Review

References (138)

1. Corte H, Manceau G, Blons H and Laurent-Puig P: MicroRNA and colorectal cancer. Digest Liver Dis 44: 195-200, 2012.
2. Jemal A, Siegel R, Ward E, Hao YP, Xu JQ and Thun MJ: Cancer Statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
3. Frost JK, Ball WC Jr, Levin ML, et al: Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins study. Am Rev Respir Dis 130: 549-554, 1984. (Pubitemid 15200003)
4. Flehinger BJ, Kimmel M and Melamed MR: The effect of surgical treatment on survival from early lung cancer. Implications for screening. Chest 101: 1013-1018, 1992.
5. Patz EF Jr, Rossi S, Harpole DH Jr, Herndon JE and Goodman PC: Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer. Chest 117: 1568-1571, 2000. (Pubitemid 30413345)
6. Yu L, Todd NW, Xing LX, et al: Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer 127: 2870-2878, 2010.
7. Subramanian J and Simon R: Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst 102: 464-474, 2010.
8. Greer KB and Cooper GS: Receipt of colonoscopy is key to reduction of colorectal cancer mortality. Gastrointest Endosc 76: 365-366, 2012.
9. Chang KC and Yew WW: What is the role of autofluorescence bronchoscopy in screening lung cancer among silicotic subjects? reply. Int J Tuberc Lung Dis 15: 1277-1278, 2011.
10. Blick CG, Nazir SA, Mallett S, et al: Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic. BJU Int 110: 84-94, 2012.
11. Ladabaum U and Song K: Projected national impact of colorectal cancer screening on clinical and economic outcomes and health services demand. Gastroenterology 129: 1151-1162, 2005. (Pubitemid 41446855)
12. Toloza EM, Harpole L and McCrory DC: Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest 123: 137S-146S, 2003. (Pubitemid 36135711)
13. van Rhijn BW, van der Poel HG and van der Kwast TH: Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 47: 736-748, 2005.
14. Thunnissen FB: Sputum examination for early detection of lung cancer. J Clin Pathol 56: 805-810, 2003.
15. Simon MA, Lokeshwar VB and Soloway MS: Current bladder cancer tests: unnecessary or beneficial? Crit Rev Oncol Hematol 47: 91-107, 2003. (Pubitemid 36945310)
16. Bassi P, De Marco V, De Lisa A, et al: Non-invasive diagnostic tests for bladder cancer: a review of the literature. Urol Int 75: 193-200, 2005. (Pubitemid 41433864)
17. Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
18. Shenouda SK and Alahari SK: MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev 28: 369-378, 2009.
19. Patnaik SK, Kannisto E, Mallick R and Yendamuri S: Overexpression of the lung cancer-prognostic miR-146b microRNAs has a minimal and negative effect on the malignant phenotype of A549 lung cancer cells. PLoS One 6: e22379, 2011.
20. Kong YW, Ferland-McCollough D, Jackson TJ and Bushell M: microRNAs in cancer management. Lancet Oncol 13: E249-E258, 2012.
21. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006. (Pubitemid 44629897)
22. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
23. Harfe BD: MicroRNAs in vertebrate development. Curr Opin Genet Dev 15: 410-415, 2005.
24. Kloosterman WP and Plasterk RHA: The diverse functions of microRNAs in animal development and disease. Dev Cell 11: 441-450, 2006. (Pubitemid 44430905)
25. Mandke P, Wyatt N, Fraser J, Bates B, Berberich SJ and Markey MP: MicroRNA-34a modulates MDM4 expression via a target site in the open reading frame. PLoS One 7: e42034, 2012.
26. Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20, 2005. (Pubitemid 40094598)
27. Chen X, Ba Y, Ma L, et al: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997-1006, 2008.
28. Mitchell PS, Parkin RK, Kroh EM, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105: 10513-10518, 2008.
29. Taylor DD and Gercel-Taylor C: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 110: 13-21, 2008. (Pubitemid 351853251)
30. Ho AS, Huang X, Cao HB, et al: Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl Oncol 3: 109-113, 2010.
31. Wu CW, Ng SSM, Dong YJ, et al: Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut 61: 739-745, 2012.
32. Xie Y, Todd NW, Liu ZQ, et al: Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer 67: 170-176, 2010.
33. Brase JC, Wuttig D, Kuner R and Sultmann H: Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer 9: 306, 2010.
34. Caby MP, Lankar D, Vincendeau-Scherrer C, Raposo G and Bonnerot C: Exosomal-like vesicles are present in human blood plasma. Int Immunol 17: 879-887, 2005. (Pubitemid 41417955)
35. van Niel G, Porto-Carreiro I, Simoes S and Raposo G: Exosomes: a common pathway for a specialized function. J Biochem 140: 13-21, 2006. (Pubitemid 44433541)
36. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ and Lotvall JO: Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9: 654-672, 2007.
37. Hunter MP, Ismail N, Zhang X, et al: Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 3: e3694, 2008.
38. Rabinowits G, Gercel-Taylor C, Day JM, Taylor DD and Kloecker GH: Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer 10: 42-46, 2009.
39. Skog J, Wurdinger T, van Rijn S, et al: Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10: 1470-1476, 2008.
40. Yu Z and Hecht NB: The DNA/RNA-binding protein, translin, binds microRNA122a and increases its in vivo stability. J Androl 29: 572-579, 2008.
41. Xie L, Chen X, Wang L, et al: Cell-free miRNAs may indicate diagnosis and docetaxel sensitivity of tumor cells in malignant effusions. BMC Cancer 10: 591, 2010.
42. Levine JS and Ahnen DJ: Clinical practice. Adenomatous polyps of the colon. N Engl J Med 355: 2551-2557, 2006. (Pubitemid 44917503)
43. Levin B, Lieberman DA, McFarland B, et al: Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 134: 1570-1595, 2008. (Pubitemid 351615355)
44. Lieberman DA and Weiss DG: One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med 345: 555-560, 2001. (Pubitemid 32772096)
45. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA and Ross ME: Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 351: 2704-2714, 2004. (Pubitemid 39665324)
46. Hewitson P, Glasziou P, Irwig L, Towler B and Watson E: Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev: CD001216, 2007. doi: 10.1002/14651858.CD001216.pub2.
47. Cotton PB, Durkalski VL, Benoit PC, et al: Computed tomographic colonography (virtual colonoscopy): a multicenter comparison with standard colonoscopy for detection of colorectal neoplasia. JAMA 291: 1713-1719, 2004. (Pubitemid 38489893)
48. Mulhall BP, Veerappan GR and Jackson JL: Meta-analysis: computed tomographic colonography. Ann Intern Med 142: 635-650, 2005. (Pubitemid 40529961)
49. Johnson CD, Chen MH, Toledano AY, et al: Accuracy of CT colonography for detection of large adenomas and cancers. New Engl J Med 359: 1207-1217, 2008.
50. Coady-Fariborzian L, Angel LP and Procaccino JA: Perforated colon secondary to virtual colonoscopy: report of a case. Dis Colon Rectum 47: 1247-1249, 2004. (Pubitemid 38857080)
51. Kanaoka S, Yoshida K, Miura N, Sugimura H and Kajimura M: Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. Gastroenterology 127: 422-427, 2004. (Pubitemid 39091890)
52. Ahlquist DA, Sargent DJ, Loprinzi CL, et al: Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med 149: 441-450, W481, 2008.
53. Brand RE, Ross ME and Shuber AP: Reproducibility of a multi-target stool-based DNA assay for colorectal cancer detection. Am J Gastroenterol 99: 1338-1341, 2004. (Pubitemid 39062273)
54. Calistri D, Rengucci C, Bocchini R, Saragoni L, Zoli W and Amadori D: Fecal multiple molecular tests to detect colorectal cancer in stool. Clin Gastroenterol Hepatol 1: 377-383, 2003. (Pubitemid 37248057)
55. Yu YJ, Majumdar AP, Nechvatal JM, et al: Exfoliated cells in stool: a source for reverse transcription-PCR-based analysis of biomarkers of gastrointestinal cancer. Cancer Epidemiol Biomarkers Prev 17: 455-458, 2008. (Pubitemid 351272800)
56. Zauber AG, Levin TR, Jaffe CC, Galen BA, Ransohoff DF and Brown ML: Implications of new colorectal cancer screening technologies for primary care practice. Med Care 46: S138-S146, 2008.
57. Aslam MI, Taylor K, Pringle JH and Jameson JS: MicroRNAs are novel biomarkers of colorectal cancer. Br J Surg 96: 702-710, 2009.
58. Ahmed FE, Jeffries CD, Vos PW, et al: Diagnostic microRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue. Cancer Genomics Proteomics 6: 281-295, 2009.
59. Link A, Balaguer F, Shen Y, et al: Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev 19: 1766-1774, 2010.
60. Kalimutho M, Del Vecchio Blanco G, Di Cecilia S, et al: Differential expression of miR-144&z.ast; as a novel fecal-based diagnostic marker for colorectal cancer. J Gastroenterol 46: 1391-1402, 2011.
61. Koga Y, Yasunaga M, Takahashi A, et al: MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev Res 3: 1435-1442, 2010.
62. Li JM, Zhao RH, Li ST, et al: Down-regulation of fecal miR-143 and miR-145 as potential markers for colorectal cancer. Saudi Med J 33: 24-29, 2012.
63. Kalimutho M, Di Cecilia S, Blanco GD, et al: Epigenetically silenced miR-34b/c as a novel faecal-based screening marker for colorectal cancer. Br J Cancer 104: 1770-1778, 2011.
64. Greenlee RT, Hill-Harmon MB, Murray T and Thun M: Cancer statistics, 2001. CA Cancer J Clin 51: 15-36, 2001. (Pubitemid 32166444)
65. Xing LX, Todd NW, Yu L, Fang HB and Jiang F: Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Modern Pathol 23: 1157-1164, 2010.
66. Akira M: High-resolution CT in the evaluation of occupational and environmental disease. Radiol Clin North Am 40: 43-59, 2002.
67. Bastarrika G, Garcia-Velloso MJ, Lozano MD, et al: Early lung cancer detection using spiral computed tomography and positron emission tomography. Am J Respir Crit Care Med 171: 1378-1383, 2005. (Pubitemid 40800510)
68. Gohagan JK, Marcus PM, Fagerstrom RM, et al: Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer 47: 9-15, 2005. (Pubitemid 39643237)
69. Swensen SJ, Jett JR, Hartman TE, et al: Lung cancer screening with CT: Mayo Clinic experience. Radiology 226: 756-761, 2003. (Pubitemid 36259152)
70. Koga H, Eguchi K, Shinkai T, et al: Preliminary evaluation of the new tumor marker, CYFRA 21-1, in lung cancer patients. Jpn J Clin Oncol 24: 263-268, 1994.
71. Sun S, Schiller JH and Gazdar AF: Lung cancer in never smokers: a different disease. Nat Rev Cancer 7: 778-790, 2007. (Pubitemid 47463669)
72. Hirsch FR, Franklin WA, Gazdar AF and Bunn PA Jr: Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin Cancer Res 7: 5-22, 2001. (Pubitemid 32110200)
73. Hassanein M, Callison JC, Callaway-Lane C, Aldrich MC, Grogan EL and Massion PP: The state of molecular biomarkers for the early detection of lung cancer. Cancer Prev Res 5: 992-1006, 2012.
74. Belinsky SA: Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 4: 707-717, 2004.
75. Castro M, Grau L, Puerta P, et al: Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer. J Transl Med 8: 86, 2010.
76. Halling KC, Rickman OB, Kipp BR, Harwood AR, Doerr CH and Jett JR: A comparison of cytology and fluorescence in situ hybridization for the detection of lung cancer in bronchoscopic specimens. Chest 130: 694-701, 2006. (Pubitemid 44423599)
77. Beane J, Sebastiani P, Whitfield TH, et al: A prediction model for lung cancer diagnosis that integrates genomic and clinical features. Cancer Prev Res 1: 56-64, 2008.
78. Yanaihara N, Caplen N, Bowman E, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189-198, 2006. (Pubitemid 43357945)
79. Greenberg AK, Rimal B, Felner K, et al: S-adenosylmethionine as a biomarker for the early detection of lung cancer. Chest 132: 1247-1252, 2007. (Pubitemid 47621000)
80. Showe MK, Vachani A, Kossenkov AV, et al: Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease. Cancer Res 69: 9202-9210, 2009.
81. Lai CY, Yu SL, Hsieh MH, et al: MicroRNA expression aberration as potential peripheral blood biomarkers for schizophrenia. PLoS One 6: e21635, 2011.
82. Peck K, Sher YP, Shih JY, Roffler SR, Wu CW and Yang PC: Detection and quantitation of circulating cancer cells in the peripheral blood of lung cancer patients. Cancer Res 58: 2761-2765, 1998. (Pubitemid 28311905)
83. van der Drift MA, Prinsen CFM, Hol BEA, et al: Can free DNA be detected in sputum of lung cancer patients? Lung Cancer 61: 385-390, 2008.
84. Zhu S, Si ML, Wu H and Mo YY: MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 282: 14328-14336, 2007. (Pubitemid 47100416)
85. Neragi-Miandoab S: Malignant pleural effusion, current and evolving approaches for its diagnosis and management. Lung Cancer 54: 1-9, 2006.
86. Wang T, Lv M, Shen S, et al: Cell-free microRNA expression profiles in malignant effusion associated with patient survival in non-small cell lung cancer. PLoS One 7: e43268, 2012.
87. Lee JH, Hong YS, Ryu JS and Chang JH: p53 and FHIT mutations and microsatellite alterations in malignancy-associated pleural effusion. Lung Cancer 44: 33-42, 2004. (Pubitemid 38317260)
88. Spector M and Pollak JS: Management of malignant pleural effusions. Semin Respir Crit Care Med 29: 405-413, 2008.
89. Topolcan O, Holubec L, Polivkova V, et al: Tumor markers in pleural effusions. Anticancer Res 27: 1921-1924, 2007. (Pubitemid 46954699)
90. Katayama H, Hiraki A, Aoe K, et al: Aberrant promoter methylation in pleural fluid DNA for diagnosis of malignant pleural effusion. Int J Cancer 120: 2191-2195, 2007. (Pubitemid 46555857)
91. Wang T, Qian X, Wang Z, et al: Detection of cell-free BIRC5 mRNA in effusions and its potential diagnostic value for differentiating malignant and benign effusions. Int J Cancer 125: 1921-1925, 2009.
92. Nair VS, Maeda LS and Ioannidis JPA: Clinical outcome prediction by microRNAs in human cancer: a systematic review. J Natl Cancer Inst 104: 528-540, 2012.
93. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
94. Snowdon J, Boag S, Feilotter H, Izard J and Siemens DR: A pilot study of urinary microRNA as a biomarker for urothelial cancer. Can Urol Assoc J 7: 28-32, 2013.
95. Yamada Y, Enokida H, Kojima S, et al: MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci 102: 522-529, 2011.
96. Ratliff TL: Urine markers for bladder cancer surveillance: a systematic review. J Urol 174: 2065-2066, 2005.
97. Sarosdy MF, Hudson MA, Ellis WJ, et al: Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology 50: 349-353, 1997. (Pubitemid 27428110)
98. Carpinito GA, Stadler WM, Briggman JV, et al: Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol 156: 1280-1285, 1996. (Pubitemid 26307594)
99. Fradet Y and Lockhard C: Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt™. Can J Urol 4: 400-405, 1997.
100. Greenlee RT, Murray T, Bolden S and Wingo PA: Cancer statistics, 2000. CA Cancer J Clin 50: 7-33, 2000. (Pubitemid 30072093)
101. Wang G, Chan ESY, Kwan BCH, et al: Expression of microRNAs in the urine of patients with bladder cancer. Clin Genitourin Cancer 10: 106-113, 2012.
102. Roos PH and Jakubowski N: Methods for the discovery of low-abundance biomarkers for urinary bladder cancer in biological fluids. Bioanalysis 2: 295-309, 2010.
103. Puerta-Gil P, Garcia-Baquero R, Jia AY, et al: miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am J Pathol 180: 1808-1815, 2012.
104. Hanke M, Hoefig K, Merz H, et al: A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 28: 655-661, 2010.
105. Veerla S, Lindgren D, Kvist A, et al: MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer 124: 2236-2242, 2009.
106. Han Y, Chen J, Zhao X, et al: MicroRNA expression signatures of bladder cancer revealed by deep sequencing. PLoS One 6: e18286, 2011.
107. Noguchi S, Mori T, Hoshino Y, et al: MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. Cancer Lett 307: 211-220, 2011.
108. Kassouf W, Black PC, Tuziak T, et al: Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol 179: 353-358, 2008. (Pubitemid 350216717)
109. Junttila TT, Laato M, Vahlberg T, et al: Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin Cancer Res 9: 5346-5357, 2003. (Pubitemid 37413590)
110. Cissell KA and Deo SK: Trends in microRNA detection. Anal Bioanal Chem 394: 1109-1116, 2009.
111. de Planell-Saguer M and Rodicio MC: Analytical aspects of microRNA in diagnostics: a review. Anal Chim Acta 699: 134-152, 2011.
112. Ach RA, Wang H and Curry B: Measuring microRNAs: comparisons of microarray and quantitative PCR measurements, and of different total RNA prep methods. BMC Biotechnol 8: 69, 2008.
113. de Planell-Saguer M and Rodicio MC: Analytical aspects of microRNA in diagnostics: a review. Anal Chim Acta 699: 134-152, 2011.
114. Sarver AL: Toward understanding the informatics and statistical aspects of micro-RNA profiling. J Cardiovasc Transl Res 3: 204-211, 2010.
115. Valoczi A, Hornyik C, Varga N, Burgyan J, Kauppinen S and Havelda Z: Sensitive and specific detection of microRNAs by northern blot analysis using LNA-modified oligonucleotide probes. Nucleic Acids Res 32: e175, 2004.
116. Pall GS, Codony-Servat C, Byrne J, Ritchie L and Hamilton A: Carbodiimide-mediated cross-linking of RNA to nylon membranes improves the detection of siRNA, miRNA and piRNA by northern blot. Nucleic Acids Res 35: e60, 2007.
117. Varallyay E, Burgyan J and Havelda Z: MicroRNA detection by northern blotting using locked nucleic acid probes. Nat Protoc 3: 190-196, 2008. (Pubitemid 351276798)
118. Chamnongpol S, Maroney PA and Nilsen TW: A rapid, quantitative assay for direct detection of microRNAs and other small RNAs using splinted ligation. Methods Mol Biol 667: 3-17, 2010.
119. Cissell KA, Rahimi Y, Shrestha S, Hunt EA and Deo SK: Bioluminescence-based detection of microRNA, miR21 in breast cancer cells. Anal Chem 80: 2319-2325, 2008. (Pubitemid 351499813)
120. Chen C, Ridzon DA, Broomer AJ, et al: Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33: e179, 2005.
121. Weaver S, Dube S, Mir A, et al: Taking qPCR to a higher level: analysis of CNV reveals the power of high throughput qPCR to enhance quantitative resolution. Methods 50: 271-276, 2010.
122. Raymond CK, Roberts BS, Garrett-Engele P, Lim LP and Johnson JM: Simple, quantitative primer-extension PCR assay for direct monitoring of microRNAs and short-interfering RNAs. RNA 11: 1737-1744, 2005. (Pubitemid 41505548)
123. Neely LA, Patel S, Garver J, et al: A single-molecule method for the quantitation of microRNA gene expression. Nat Methods 3: 41-46, 2006. (Pubitemid 43135348)
124. Kloosterman WP, Wienholds E, de Bruijn E, Kauppinen S and Plasterk RHA: In situ detection of miRNAs in animal embryos using LNA-modified oligonucteotide probes. Nat Methods 3: 27-29, 2006. (Pubitemid 43135345)
125. de Planell-Saguer M, Rodicio MC and Mourelatos Z: Rapid in situ codetection of noncoding RNAs and proteins in cells and formalin-fixed paraffin-embedded tissue sections without protease treatment. Nat Protoc 5: 1061-1073, 2010.
126. Obernosterer G, Martinez J and Alenius M: Locked nucleic acid-based in situ detection of microRNAs in mouse tissue sections. Nat Protoc 2: 1508-1514, 2007. (Pubitemid 46952329)
127. Nelson PT, Baldwin DA, Kloosterman WP, Kauppinen S, Plasterk RHA and Mourelatos Z: RAKE and LNA-ISH reveal microRNA expression and localization in archival human brain. RNA 12: 187-191, 2006. (Pubitemid 43121922)
128. Liu CG, Calin GA, Volinia S and Croce CM: MicroRNA expression profiling using microarrays. Nat Protoc 3: 563-578, 2008. (Pubitemid 351516752)
129. Li W and Ruan KC: MicroRNA detection by microarray. Anal Bioanal Chem 394: 1117-1124, 2009.
130. Nelson PT, Baldwin DA, Scearce LM, Oberholtzer JC, Tobias JW and Mourelatos Z: Microarray-based, high-throughput gene expression profiling of microRNAs. Nat Methods 1: 155-161, 2004.
131. Takada S and Mano H: Profiling of microRNA expression by mRAP. Nat Protoc 2: 3136-3145, 2007.
132. Volinia S, Calin GA, Liu CG, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261, 2006. (Pubitemid 43271657)
133. Weber JA, Baxter DH, Zhang SL, et al: The microRNA spectrum in 12 body fluids. Clin Chem 56: 1733-1741, 2010.
134. Kanaan Z, Rai SN, Eichenberger MR, et al: Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann Surg 256: 544-551, 2012.
135. Li BS, Zhao YL, Guo G, et al: Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS One 7: e41629, 2012.
136. Zhang X, Cui L, Ye G, et al: Gastric juice microRNA-421 is a new biomarker for screening gastric cancer. Tumour Biol 33: 2349-2355, 2012.
137. Janakiram NB and Rao CV: Molecular markers and targets for colorectal cancer prevention. Acta Pharmacol Sin 29: 1-20, 2008.
138. Dong Y, Wu WK, Wu CW, Sung JJ, Yu J and Ng SS: MicroRNA dysregulation in colorectal cancer: a clinical perspective. Br J Cancer 104: 893-898, 2011.